NASDAQ Shariah screener · October 2026

Is IDEXX Laboratories, Inc. (IDXX) Halal?

PASS

IDEXX Laboratories, Inc. · NASDAQ: IDXX · Healthcare

The short answer

Yes — IDEXX Laboratories (IDXX) passes this Shariah stock screen. Its veterinary diagnostics business (VetLab instruments and consumables, rapid assay kits, reference labs, vet software, plus water and livestock testing) has no prohibited lines; its small human-diagnostics/outlicensing line is about 0.4% of revenue. Interest-bearing debt of ~$968.9M ($519.0M line of credit + $150.0M current + $299.9M long-term, Jun 30, 2026) is about 2.3% of its ~$41.68B market cap ($517.75/share, Oct 2, 2026) — far under the ~33% ceiling. Interest income of $3.01M (FY2025 10-K, disclosed line) is about 0.07% of $4,303.7M revenue — far under the 5% limit. Zoya independently rates IDXX Shariah-compliant (September 2026); no Musaffa or ShariaPortfolio rating was found — honestly reported as absent.

Gate 1 — Business activity: PASS

IDEXX Laboratories, Inc. (NASDAQ: IDXX), headquartered in Westbrook, Maine, has three reportable segments per its FY2025 Form 10-K. The Companion Animal Group (CAG) — about $3,953.3M of FY2025's $4,303.7M revenue — provides veterinary diagnostic products and services: IDEXX VetLab analyzers and consumables, rapid assay kits, reference laboratory diagnostic and consulting services, and veterinary software, services and diagnostic imaging systems. Water ($201.1M) provides testing solutions for detecting microbiological parameters in water. Livestock, Poultry and Dairy (LPD) ($131.8M) provides diagnostic tests for livestock and poultry health and milk quality and safety. The Other line ($17.5M) combines its human medical diagnostic business with outlicensing arrangements. None of these lines are prohibited lines — no alcohol, gambling, pork, conventional banking/insurance, tobacco, cannabis, or adult entertainment. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

At June 30, 2026 the Q2 2026 condensed balance sheet (reported in the August 4, 2026 earnings release) shows $519.0M drawn on the line of credit, $150.0M current portion of long-term debt, and $299.9M of long-term debt (net of current portion) — total interest-bearing debt of about $968.9M. Against a market cap of about $41.68B (Finnhub, $517.75 per share, October 2, 2026), debt ÷ market cap is about 2.3%, far below the ~33% ceiling. Cash and cash equivalents of $196.9M are about 0.5% of market cap, within the ~33% guideline. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

The FY2025 Form 10-K discloses interest income of $3.01M for the year ended December 31, 2025 (vs $12.7M in 2024, as money market investments declined), broken out in the segment-profit reconciliation and the MD&A. Against total revenue of $4,303.7M, interest income is about 0.07% of revenue — far below the 5% non-compliant income ceiling. (The quarterly income statements present only a single 'Non-operating income (expense), net' line; the 10-K's explicit interest-income disclosure is the primary basis for this gate.) Gate 3 passes. Facts only.

Key figures used

Business: veterinary diagnostics leader — Companion Animal Group ($3,953.3M of $4,303.7M FY2025 revenue): VetLab analyzers/consumables, rapid assay kits, reference labs, vet software and imaging; Water $201.1M; LPD $131.8M; Other (human diagnostics + outlicensing) $17.5M; ~11,000 employees, 175+ countries
Interest-bearing debt: $968.9M at Jun 30, 2026 (line of credit $519.0M + current LTD $150.0M + long-term debt $299.9M) — debt ÷ market cap ≈ 2.3%, far under the ~33% ceiling
Market cap: ~$41.68B ($517.75/share, Finnhub, Oct 2, 2026); cash $196.9M ≈ 0.5% of market cap
Interest income: $3.01M (FY2025 10-K, disclosed line) vs revenue $4,303.7M — ≈0.07% of revenue, far under the 5% non-compliant income ceiling; 2024 interest income was $12.7M
Q2 2026: revenue $1,216.6M (+10% reported, +9% organic); diluted EPS $4.27; 2026 revenue guidance $4,700–$4,745M; pays no dividend
Zoya lists IDXX as Shariah-compliant (Sept 2026); no Musaffa or ShariaPortfolio rating found — reported as absent, not invented

Frequently asked questions

What does IDEXX Laboratories do?

IDEXX Laboratories (NASDAQ: IDXX), headquartered in Westbrook, Maine, is a global leader in pet healthcare innovation. Its core Companion Animal Group (CAG) business sells diagnostic analyzers and consumables (IDEXX VetLab instruments, rapid assay kits), reference laboratory diagnostic and consulting services, and veterinary practice software (ezyVet and related cloud products) plus diagnostic imaging systems. It also operates two smaller segments: Water (microbiology testing products for detecting bacteria in water) and Livestock, Poultry and Dairy (LPD) diagnostics, plus a small Other line of human medical diagnostics (OPTI Medical) and outlicensing arrangements. IDEXX employs about 11,000 people and serves customers in more than 175 countries and territories.

Why does IDEXX Laboratories pass this Shariah stock screen?

IDEXX Laboratories passes all three gates of this screen. Gate 1 (business): its lines — veterinary diagnostics, reference labs, water microbiology testing, livestock and dairy diagnostics, and human point-of-care diagnostics — contain none of the prohibited lines (no alcohol, gambling, pork, conventional banking or insurance, tobacco, cannabis, or adult entertainment). Gate 2 (debt): at June 30, 2026 it carried $968.9M of interest-bearing debt against a market cap of about $41.68B, a ratio of about 2.3%, far below the ~33% ceiling. Gate 3 (non-compliant income): interest income of $3.01M for FY2025 was about 0.07% of revenue ($4,303.7M), far below the ~5% limit. Zoya also independently lists IDXX as Shariah-compliant as of September 2026. This is a factual screen, not a religious ruling — consult a qualified scholar for personal guidance.

What is IDEXX Laboratories' interest-bearing debt ratio?

At June 30, 2026 IDEXX reported a $519.0M line-of-credit draw, $150.0M current portion of long-term debt, and $299.9M of long-term debt (net of current portion) — total interest-bearing debt of about $968.9M — in its Q2 2026 condensed balance sheet (reported via the August 4, 2026 earnings release). Against a market capitalization of about $41.68B (Finnhub, $517.75 per share, October 2, 2026), debt ÷ market cap is about 2.3%, far below the ~33% ceiling. Cash and cash equivalents of $196.9M are about 0.5% of market cap, within the ~33% guideline. The financial-structure gate passes.

What is IDEXX Laboratories' non-compliant income ratio?

IDEXX's FY2025 Form 10-K discloses interest income of $3.01M for the year ended December 31, 2025 (down from $12.7M in 2024 as money market investments fell) in the segment-profit reconciliation and the MD&A. Against total revenue of $4,303.7M, interest income is about 0.07% of revenue — far below the 5% non-compliant income ceiling. The income statement presents only a single 'Non-operating income (expense), net' line (-$8.3M in Q2 2026), but the 10-K's explicit interest-income disclosure is the primary basis for this gate, which passes.

Do Zoya, Musaffa, or ShariaPortfolio cover IDEXX Laboratories?

Zoya covers IDXX and lists it as Shariah-compliant as of September 2026 (zoya.finance/stocks/idxx), consistent with this screen's PASS. No Musaffa stock page for IDXX (NASDAQ) was found in public search results, and no public ShariaPortfolio rating for IDXX was found — honestly reported as absent, not invented. This page applies the screen directly from the company's filings: the FY2025 Form 10-K (filed February 20, 2026) and the Q2 2026 results (August 4, 2026, condensed balance sheet and statement of operations).

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).